Expression of alternatively spliced Runx2 in multiple myeloma patients and a shift in expression in response to thalidomide treatment.

被引：0
|
作者：
Bose, N
Bergemann, H
Westendorf, JJ
Rajkumar, SV
Masellis, AM
机构：
[1] Virginia Piper Canc Inst, Minneapolis, MN USA
[2] Univ Minnesota, Orthopaed Surg & Canc Ctr, Minneapolis, MN 55455 USA
[3] Mayo Clin & Mayo Fdn, Rochester, MN 55905 USA
来源：
JOURNAL OF BONE AND MINERAL RESEARCH | 2003年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S310 / S310
页数：1
相关论文
共 50 条
  • [21] High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance
    Broyl, Annemiek
    Kuiper, Rowan
    van Duin, Mark
    van der Holt, Bronno
    el Jarari, Laila
    Bertsch, Uta
    Zweegman, Sonja
    Buijs, Arjan
    Hose, Dirk
    Lokhorst, Henk M.
    Goldschmidt, Hartmut
    Sonneveld, Pieter
    BLOOD, 2013, 121 (04) : 624 - 627
  • [22] High Expression of the Thalidomide-Binding Protein Cereblon (CRBN) Is Associated with Improved Clinical Response in Patients with Multiple Myeloma Treated with Lenalidomide and Dexamethasone
    Heintel, Daniel
    Bolomsky, Arnold
    Schreder, Martin
    Pfeifer, Sabine
    Zojer, Niklas
    Jaeger, Ulrich
    Ludwig, Heinz
    BLOOD, 2011, 118 (21) : 1242 - 1243
  • [23] Association between runx2 expression and survival outcome of cancer patients: a meta-analysis of 12 cohorts
    Xu, Fei
    Zheng, Hong
    You, Guoling
    Song, Pingping
    Pan, Qiuhui
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2017, 10 (11): : 14989 - 15002
  • [24] Runx2 mRNA Expression in the Tissue, Serum, and Circulating Non-Hematopoietic Cells of Patients with Thyroid Cancer
    Carbonare, Luca Dalle
    Frigo, Anna
    Francia, Giuseppe
    Davi, Maria Vittoria
    Donatelli, Luca
    Stranieri, Chiara
    Brazzarola, Paolo
    Zatelli, Maria Chiara
    Menestrina, Fabio
    Valenti, Maria Teresa
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2012, 97 (07): : E1249 - E1256
  • [25] RESPONSE TO INTERFERON THERAPY IN PATIENTS WITH MULTIPLE-MYELOMA CORRELATES WITH EXPRESSION OF THE BCL-2 ONCOPROTEIN
    SANGFELT, O
    OSTERBORG, A
    GRANDER, D
    ANDERBRING, E
    OST, A
    MELLSTEDT, H
    EINHORN, S
    INTERNATIONAL JOURNAL OF CANCER, 1995, 63 (02) : 190 - 192
  • [26] The influence of thalidomide therapy on cytokine secretion, immunophenotype, BCL-2 expression and microvessel density in patients with resistant or relapsed multiple myeloma
    Dmoszynska, A
    Podhorecka, M
    Manko, J
    Bojarska-Junak, A
    Rolinski, J
    Skomra, D
    NEOPLASMA, 2005, 52 (02) : 175 - 181
  • [27] Expression analysis of genes associated with human osteosarcoma tumors shows correlation of RUNX2 overexpression with poor response to chemotherapy
    Bekim Sadikovic
    Paul Thorner
    Susan Chilton-MacNeill
    Jeff W Martin
    Nilva K Cervigne
    Jeremy Squire
    Maria Zielenska
    BMC Cancer, 10
  • [28] Expression analysis of genes associated with human osteosarcoma tumors shows correlation of RUNX2 overexpression with poor response to chemotherapy
    Sadikovic, Bekim
    Thorner, Paul
    Chilton-MacNeill, Susan
    Martin, Jeff W.
    Cervigne, Nilva K.
    Squire, Jeremy
    Zielenska, Maria
    BMC CANCER, 2010, 10
  • [29] PROTEASOME INHIBITOR TREATMENT RESPONSE CAN BE PREDICTED BY GENE EXPRESSION PROFILING IN MULTIPLE MYELOMA
    Van Vliet, M. H.
    Kuiper, R.
    Broijl, A.
    Van Duin, M.
    de Best, L.
    van Beers, E. H.
    Sonneveld, P.
    HAEMATOLOGICA, 2014, 99 : 494 - 495
  • [30] Using single cell gene expression to develop treatment response predictions in multiple myeloma
    Scolnick, Jonathan
    Xu, Stacy
    De Mel, Sanjay
    Soekojo, Cinnie Yentia
    Chng, Wee Joo
    CANCER RESEARCH, 2022, 82 (12)
12345